Premium
Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib
Author(s) -
Wongchenko Matthew J.,
Ribas Antoni,
Dréno Brigitte,
Ascierto Paolo A.,
McArthur Grant A.,
Gallo Jorge D.,
Rooney Isabelle A.,
Hsu Jessie,
Koeppen Hartmut,
Yan Yibing,
Larkin James
Publication year - 2018
Publication title -
pigment cell and melanoma research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.618
H-Index - 105
eISSN - 1755-148X
pISSN - 1755-1471
DOI - 10.1111/pcmr.12670
Subject(s) - vemurafenib , medicine , hazard ratio , oncology , melanoma , cohort , metastatic melanoma , cancer research , cancer , confidence interval
Summary The prognostic significance of programmed death ligand‐1 ( PD ‐L1) on treatment outcomes in patients receiving BRAF with or without MEK inhibitors is not well understood. This retrospective exploratory analysis evaluated the association of tumour PD ‐L1 expression with progression‐free survival ( PFS ) and overall survival ( OS ) among 210 patients in the co BRIM trial treated with cobimetinib plus vemurafenib or placebo plus vemurafenib. In the vemurafenib cohort, there was a trend of increased PFS and OS in those with PD ‐L1 + melanoma, with hazard ratios ( HR s; PD ‐L1 + vs. PD ‐L1 − ) of 0.70 (95% CI , 0.46–1.07) and 0.69 (95% CI , 0.42–1.13) for PFS and OS , respectively. However, in patients treated with cobimetinib plus vemurafenib, a similar trend was not observed with HR s ( PD ‐L1 + versus PD ‐L1 − ) of 1.04 (95% CI , 0.66–1.68) and 0.94 (95% CI , 0.57–1.57) for PFS and OS , respectively. The combination cobimetinib plus vemurafenib appears to overcome the poor prognosis associated with low PD ‐L1 expression.